Cancer immunotherapy company Compugen Ltd (NASDAQ:CGEN) reported on Monday the receipt of US FDA investigational new drug (IND) application for its immuno-oncology therapeutic antibody COM902 targeting TIGIT in patients with advanced malignancies.
Upon receipt of IND from the US FDA, the company plans to launch a Phase 1 clinical trial in patients with advanced malignancies for whom standard of care therapies are currently ineffective.
Expected to begin at multiple centres in the US in early 2020, the clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of COM902, according to the company.
COM902, a high affinity, fully human antibody targeting TIGIT, was developed by the company for combination treatment with COM701.
Based on preclinical data, the TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T cell activation and increase anti-tumor immune responses. Parallel inhibition of TIGIT and PVRIG results in synergistic effects on effector T cell function and tumor growth inhibition in various model systems that can be further increased with the addition of PD-1 blockade. The TIGT discovery was published by Compugen in October 2009 in the Proceedings of the National Academy of Sciences (PNAS).
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886